

# NLRP3/NALP3 (human) monoclonal antibody (Nalpy3-b)

This antibody is covered by our [Worry-Free Guarantee](#).

Citations: 28

[View Online »](#)



Ordering Information

[Order Online »](#)

ALX-804-819-C100	100µg
------------------	-------


Manuals, SDS & CofA

[View Online »](#)




Hypoxia reduces inflammatory processes and induces autophagy in *Il-10*<sup>-/-</sup> mice. a, b, c, d, e, f and g WT, *Nlrp3*<sup>-/-</sup>, *Il-10*<sup>-/-</sup>, and *Il-10*<sup>-/-</sup>*Nlrp3*<sup>-/-</sup> double knockout mice were subjected to normoxia (N, 21% O<sub>2</sub>) or hypoxia (H, 8% O<sub>2</sub>). After 18 h, mice were killed and colon biopsies were collected. Statistical analysis was performed using one-way ANOVA followed by Tukey's post-test. Results represent mean + s.e.m., WT mice under normoxia: n = 5, WT mice under hypoxia: n = 5; *Nlrp3*<sup>-/-</sup> mice under normoxia: n = 4; *Nlrp3*<sup>-/-</sup> mice under hypoxia: n = 5; *Il-10*<sup>-/-</sup> mice under hypoxia: n = 4; *Il-10*<sup>-/-</sup> mice under hypoxia: n = 4; *Il-10*<sup>-/-</sup>*Nlrp3*<sup>-/-</sup> mice under normoxia: n = 7; *Il-10*<sup>-/-</sup>*Nlrp3*<sup>-/-</sup> mice under hypoxia: n = 9, \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001. h Total protein was isolated and western blot performed. LC3-I and LC3-II bands were quantified, and autophagy was measured by variations in the ratio of LC3-II/LC3-I and the total amount of LC3 (LC3-I plus LC3-II) relative to β-actin

Image collected and cropped by CiteAb under a CC-BY license from the following publication: Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation. *Nat Commun* (2017)




DMOG reduces inflammation and induces autophagy in DSS-treated mice. a, b, c, d, e and f WT mice were administered with 2% DSS for 5 days and co-administered with 8 mg DMOG injected intraperitoneally every second day. Weight loss was monitored during the course of treatment a. After a recovery period, mice were killed at day 9 colon biopsies were collected and colon length was measured b. Mucosal damage was assessed by colonoscopy c and murine endoscopic score of colitis severity (MEICS) was calculated d. H&E staining of distal colon sections displayed a significant decrease in barrier breakdown and inflammatory infiltrate in DMOG-treated mice e. Scale bar, 100  $\mu$ m. Total histological score at day 9 was calculated as the sum of epithelial damage and infiltration score f. g, h, i, j, k, l and m distal colon biopsies were collected and transcript analysis was performed. Statistical analysis was performed using Student t-test. Results represent mean + s.e.m., DSS-treated mice administered with PBS: n = 5; DSS-treated mice administered with DMOG: n = 5; \*P < 0.05; \*\*P < 0.01. n Total protein was isolated and Western blot performed. LC3-I and LC3-II bands were quantified, and autophagy was measured by variations in the ratio of LC3-II/LC3-I and the total amount of LC3 (LC3-I plus LC3-II) relative to  $\beta$ -actin

Image collected and cropped by CiteAb under a CC-BY license from the following publication: Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation. *Nat Commun* (2017)




Hypoxia reduces inflammatory signaling pathways and NLRP3 expression and induces autophagy in IECs. a HT-29 cells were subjected to normoxia and hypoxia at the indicated times in the absence or presence of 10  $\mu$ g/ml LPS. Autophagy was measured by variations in the ratio of LC3-II/LC3-I and the total amount of LC3 (LC3-I plus LC3-II) relative to  $\beta$ -actin. Results are representative of two independent experiments. b, c and d HT-29 cells were subjected to normoxia and hypoxia for the indicated periods in the absence or presence of 10  $\mu$ g/ml LPS, followed by transcript analysis. Statistical analysis was performed using one-way ANOVA followed by Tukey's post-test. Results represent mean + s.e.m. of two independent experiments done in triplicate, \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001; ns not significant. e HT-29 cells were subjected to normoxia or hypoxia in the presence and absence of 10  $\mu$ g/ml LPS and 20  $\mu$ M of MG132. Results are representative of two independent experiments. f and g Putative binding sites for HIF-1 $\alpha$  and NF- $\kappa$ B were found in the p62 f and NLRP3 g promoters using Genomatix software tools. Numbers under the boxes indicate the distance from the transcription start site. HT-29 cells were subjected to normoxia (21% O<sub>2</sub>) or hypoxia (0.2% O<sub>2</sub>) for 6 h and 24 h. ChIP analysis was performed using antibodies against HIF-1 $\alpha$  and NF- $\kappa$ B for immunoprecipitation. PCR was performed using the promoter-specific primers




Hypoxia reduces inflammatory processes and induces autophagy in the DSS mouse model of colitis. a, b, c, d, e, f and g WT and *Nlrp3*<sup>-/-</sup> mice were administered with DSS or DSS-free water and subjected to normoxia (N, 21% O<sub>2</sub>) or hypoxia (H, 8% O<sub>2</sub>). After 18 h, mice were killed and colon biopsies were collected. Statistical analysis was performed using one-way ANOVA followed by Tukey's post-test. Results represent mean + s.e.m., WT mice under normoxia: n = 5, WT mice under normoxia: n = 5, DSS-treated WT mice under normoxia: n = 6; *Nlrp3*<sup>-/-</sup> mice under normoxia: n = 5; DSS-treated *Nlrp3*<sup>-/-</sup> mice under normoxia: n = 6; WT mice under hypoxia: n = 4, DSS-treated WT mice under hypoxia: n = 5; *Nlrp3*<sup>-/-</sup> mice under hypoxia: n = 3; DSS-treated *Nlrp3*<sup>-/-</sup> mice under hypoxia: n = 3, \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001. h Total protein was isolated and western blot performed. LC3-I and LC3-II bands were quantified, and autophagy was measured by variations in the ratio of LC3-II/LC3-I and the total amount of LC3 (LC3-I plus LC3-II) relative to β-actin

Image collected and cropped by CiteAb under a CC-BY license from the following publication: Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation. *Nat Commun* (2017)



NLRP3 regulates autophagy through an inflammasome-independent mechanism via direct binding to mTOR. a HT-29 cells were transfected with NLRP3-specific siRNA or negative control siRNA using Lipofectamine RNAiMAX. Forty-eight hours after transfection, total protein was isolated and western blot performed. Quantification of the ratio of LC3-II/LC3-I and the total amount of LC3 (LC3-I plus LC3-II) relative to β-actin is presented. Statistical analysis was performed using Student t-test. Results represent mean + s.e.m. of three independent experiments, \*P < 0.05. b HT-29 cells were subjected to normoxia (21% O<sub>2</sub>) or hypoxia (0.2% O<sub>2</sub>) for 24 h in the presence and absence of LPS. Co-IP using NLRP3 antibody was performed, followed by anti-mTOR immunoblotting. Quantification relative to cells subjected to normoxia in the absence of LPS after normalization to NLRP3 is presented. Statistical analysis was performed using one-way ANOVA followed by Tukey's post-test. Results represent mean of three independent experiments + s.e.m., \*\*P < 0.01

Image collected and cropped by CiteAb under a CC-BY license from the following publication: Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation. *Nat Commun* (2017)



NLRP3 regulates autophagy through an inflammasome-independent mechanism via direct binding to mTOR. a HT-29 cells were transfected with NLRP3-specific siRNA or negative control siRNA using Lipofectamine RNAiMAX. Forty-eight hours after transfection, total protein was isolated and western blot performed. Quantification of the ratio of LC3-II/LC3-I and the total amount of LC3 (LC3-I plus LC3-II) relative to  $\beta$ -actin is presented. Statistical analysis was performed using Student t-test. Results represent mean + s.e.m. of three independent experiments, \* $P < 0.05$ . b HT-29 cells were subjected to normoxia (21% O<sub>2</sub>) or hypoxia (0.2% O<sub>2</sub>) for 24 h in the presence and absence of LPS. Co-IP using NLRP3 antibody was performed, followed by anti-mTOR immunoblotting. Quantification relative to cells subjected to normoxia in the absence of LPS after normalization to NLRP3 is presented. Statistical analysis was performed using one-way ANOVA followed by Tukey's post-test. Results represent mean of three independent experiments + s.e.m., \*\* $P < 0.01$

Image collected and cropped by CiteAb under a CC-BY license from the following publication: Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation. *Nat Commun* (2017)

# Handling & Storage

Handling	Avoid freeze/thaw cycles.
Short Term Storage	+4°C
Long Term Storage	-20°C
Shipping	Blue Ice

## Regulatory Status

RUO - Research Use Only

# Product Details

Alternative Name	NACHT-, LRR- and PYD-containing protein 3, CIAS1, Cryopyrin, Cold autoinflammatory syndrome 1 protein, PYPAF1, PYRIN-containing APAF1-like protein 1
Application	IHC (FS), IP, WB
Clone	Nalpy3-b
Formulation	Liquid. In PBS containing 0.02% sodium azide.
Host	Mouse
Immunogen	Recombinant human NLRP3/NALP3 (NACHT-, LRR- and PYD-containing protein 3) (pyrin domain).
Isotype	IgG1
Recommendation Dilutions/Conditions	Immunoprecipitation (1:50)Western Blot (1:1,000)Suggested dilutions/conditions may not be available for all applications.Optimal conditions must be determined individually for each application.
Source	Purified from concentrated hybridoma tissue culture supernatant.
Species Reactivity	Human
Specificity	Detects endogenous protein by IP and WB.
UniProt ID	Q96P20

Worry-free Guarantee

This antibody is covered by our [Worry-Free Guarantee](#)

Last modified: May 29, 2024



ENZO LIFE SCIENCES,  
INC.  
Phone: 800.942.0430  
[info-usa@enzolifesciences.com](mailto:info-usa@enzolifesciences.com)

European Sales Office  
ENZO LIFE SCIENCES  
(ELS) AG  
Phone: +41 61 926 8989  
[info-eu@enzolifesciences.com](mailto:info-eu@enzolifesciences.com)

Belgium, The Netherlands  
& Luxembourg  
Phone: +32 3 466 0420  
[info-be@enzolifesciences.com](mailto:info-be@enzolifesciences.com)

France  
Phone: +33 472 440 655  
[info-fr@enzolifesciences.com](mailto:info-fr@enzolifesciences.com)

Germany  
Phone: +49 7621 5500 526  
[info-de@enzolifesciences.com](mailto:info-de@enzolifesciences.com)

UK & Ireland  
Phone (UK customers):  
0845 601 1488  
Phone: +44 1392 825900  
[info-uk@enzolifesciences.com](mailto:info-uk@enzolifesciences.com)